CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival.

BACKGROUND AND OBJECTIVES The chemokine receptor CXCR3, involved in chemotaxis, is expressed on normal and malignant B cells and plasma cells. Recent data suggest that CXCR3-binding chemokines may also regulate proliferation and survival in endothelial cells through the interaction with two distinct isoforms of CXCR3 (CXCR3-A and CXCR3-B). DESIGN AND METHODS We evaluated the potential expression of CXCR3 isoforms in myeloma cells, also investigating whether CXCR3 expression is affected by cell cycle and apoptosis. Furthermore, we assessed the effect of CXCR3 activation on myeloma cell proliferation and survival. RESULTS We found that CXCR3 is widely expressed on human myeloma cell lines and freshly purified myeloma cells. The presence of both CXCR3 isoforms, CXCR3-A and CXCR3-B, was observed in myeloma cells with different ratios of expression. Interestingly, we found that CXCR3 expression in myeloma cell was cell cycle dependent and that myeloma growth factors inhibited CXCR3 expression in myeloma cells. On the other hand, we found that FAS (CD95)-mediated apoptosis up-regulated CXCR3 expression. A similar behavior was observed for the CXCR3-binding chemokines. Finally we found that the activation of CXCR3 on myeloma cells by CXCL10/IP-10 partially blunted FAS-mediated apoptosis in myeloma cells that express CXCR3-A and that high concentrations of CXCL10/IP-10 inhibit myeloma cell proliferation. INTERPRETATION AND CONCLUSIONS Our data indicate that myeloma cells express the CXCR3 system with patterns correlated to cell cycle and apoptosis and that CXCR3 activation may affect myeloma cell survival and proliferation.

[1]  N. Munshi,et al.  The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. , 2006, European journal of cancer.

[2]  S. Kelsen,et al.  CXCR3 surface expression in human airway epithelial cells: cell cycle dependence and effect on cell proliferation. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[3]  M. Burdick,et al.  Cancer CXC chemokine networks and tumour angiogenesis. , 2006, European journal of cancer.

[4]  Andreas Radbruch,et al.  Long-lived plasma cells in immunity and immunopathology. , 2006, Immunology letters.

[5]  Z. Brown,et al.  Chemokine Receptors , 2006, Treatments in respiratory medicine.

[6]  Andreas Radbruch,et al.  Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. , 2005, Blood.

[7]  Sakae Tanaka,et al.  Monokine induced by interferon-γ is induced by receptor activator of nuclear factor κB ligand and is involved in osteoclast adhesion and migration , 2005 .

[8]  P. Romagnani,et al.  CXCR3-binding chemokines: novel multifunctional therapeutic targets. , 2005, Current drug targets. Immune, endocrine and metabolic disorders.

[9]  R. Ransohoff,et al.  Chemokine receptor CXCR3: an unexpected enigma. , 2005, Current topics in developmental biology.

[10]  D. Ribatti,et al.  CXCR3-binding chemokines in multiple myeloma. , 2004, Cancer letters.

[11]  H. Kaufmann,et al.  New insights into the pathophysiology of multiple myeloma. , 2003, The Lancet. Oncology.

[12]  R. Bataille,et al.  Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. , 2003, Blood.

[13]  Sergio Romagnani,et al.  An Alternatively Spliced Variant of CXCR3 Mediates the Inhibition of Endothelial Cell Growth Induced by IP-10, Mig, and I-TAC, and Acts as Functional Receptor for Platelet Factor 4 , 2003, The Journal of experimental medicine.

[14]  G. Nilsson,et al.  Expression and function of chemokine receptors in human multiple myeloma , 2003, Leukemia.

[15]  Andreas Radbruch,et al.  Chemotactic Responsiveness Toward Ligands for CXCR3 and CXCR4 Is Regulated on Plasma Blasts During the Time Course of a Memory Immune Response1 , 2002, The Journal of Immunology.

[16]  P. Loetscher,et al.  Agonistic and antagonistic activities of chemokines , 2001, Journal of leukocyte biology.

[17]  M. Serio,et al.  Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. , 2001, The Journal of clinical investigation.

[18]  D. Dorfman,et al.  The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. , 2000, Blood.

[19]  D. Dorfman,et al.  The chemokine receptor CXCR 3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia , 2000 .

[20]  L. Trentin,et al.  The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. , 1999, The Journal of clinical investigation.

[21]  J. Teruya-Feldstein,et al.  Mig, the monokine induced by interferon-γ, promotes tumor necrosis in vivo , 1997 .

[22]  J. Farber.  Mig and IP‐10: CXC chemokines that target lymphocytes , 1997, Journal of leukocyte biology.

[23]  J. Teruya-Feldstein,et al.  Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. , 1997, Blood.

[24]  B Dewald,et al.  Human chemokines: an update. , 1997, Annual review of immunology.

[25]  K. Takatsuki,et al.  Fas/Apo-1 (CD95)-mediated and CD95-independent apoptosis of malignant plasma cells. , 1996, Leukemia & lymphoma.

[26]  J. Westendorf,et al.  Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines. , 1995, Blood.